已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFRβ Positive Acute Lymphoblastic Leukemia

达沙替尼 医学 微小残留病 长春新碱 内科学 肿瘤科 Blinatumoab公司 白血病 免疫学 癌症研究 化疗 环磷酰胺 髓系白血病 伊马替尼 淋巴细胞白血病
作者
Fara Petruzziello,Giovanna Giagnuolo,Giovanni Cazzaniga,Giuliana Beneduce,Franco Locatelli,Pio Stellato,Grazia Fazio,Giuseppe Mirabelli,Giuseppe Menna,Rosanna Parasole
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 5213-5213 被引量:3
标识
DOI:10.1182/blood-2018-99-113829
摘要

Abstract Recently, a novel subgroup of B Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL), called Philadelphia-like (Ph-like) ALL, has been described. This high-risk group, despite the absence of BCR-ABL1 rearrangement, shows genomic abnormalities that result in aberrant expression of cytokine receptors genes or tyrosine-kinase-activating signaling. These patients are poor responder to conventional chemotherapy but potentially sensitive to Tyrosine-Kinase Inhibitors (TKIs). Herein we report the case of a 10 year-old girl who received diagnosis of precursor B-ALL on February 2018. She started therapy according to observational protocol ALL 2017 of the Italian Association of Pediatric Hemato-Oncology (AIEOP). After pre-phase, the patient resulted prednisone poor responder and continued induction therapy, including daunorubicin, vincristine, PEG-L-Asparaginase, prednisone and intrathecal methotrexate. Bone marrow evaluation showed persistence of disease on day 15 (88% of lymphoblasts) and 33 (60% of blasts) in flow cytometry. At the end of IA induction phase, Minimal Residual Disease (MRD) in RT-PCR showed high positivity (marker 1 = 7.2x10-1, marker 2= 8.11x10-1). At this time, further molecular studies, using RNA targeted next generation sequencing (PanCancer, Illumina), revealed the presence of EBF1-PDGFRβ gene fusion. Since the patient was resistant to conventional therapy and literature's evidences demonstrated potential sensitivity of EBF1-PDGFRβ to TKIs therapy, we decided to add dasatinib, a second generation TKI, to IB induction, with cyclophosphamide, cytarabine and 6-mercapthopurine. After one week of therapy, clinical course was complicated by Klebsiella Pneumoniae sepsis, followed by digestive hemorrhage. Since we retained that the hemorrhagic event could be related to dasatinib, the drug was temporarily discontinued. However, bone marrow evaluation, after only 10 days of dasatinib administration, showed hematologic remission (3% of lymphoblast) and MRD reduction >1 logarithm (markers 1=1-10-2 e markers 2= 9.9 x 10-3). Given the resistance to chemotherapy alone and the excellent response to dasatinib but its related toxicity in combination, we decided to start immunotherapy with blinatumomab, a bi-specific CD3-CD19 monoclonal antibody, alternated to dasatinib, in order to achieve MRD negativity before to proceed with allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling. The patient received 2 courses of blinatumomab for 28 days continuous infusion (15 mcg/mq days 1-28), interspersed by 15 days of dasatinib (60 mg/mq/day). After the first cycle the patient achieved complete hematological remission and MRD negativity. MRD negativity was confirmed after first course of dasatinib, second course of blinatumomab and second course of dasatinib. Dasatinib, given alone, was well tolerated and no serious adverse event were reported. Actually, the patient is undergoing HSCT by HLA-identical sister. To our knowledge, only few cases of EBF1-PDGFRβ ALL, treated with TKIs, are described in literature and this is the first in which MRD negativity was obtained with a sequential combination of dasatinib and blinatumumomab, a chemo-free approach, showing efficacy and good tolerability. This case highlights also that screening for targetable lesions at diagnosis or in case of resistance to induction phase is mandatory to identify patients who might benefit from alternative therapies as TKIs, immunotherapy or their combination. A longer follow-up is required to definitively establish the long-term efficacy of this biological approach in our patient. Nevertheless, it is interesting to speculate that alternative treatment with TKIs or immunotherapy could avoid, in the future, an intensive chemotherapy, or probably a transplant approach in selected patients, in order to achieve a durable cure in these Ph-like patients. Disclosures Locatelli: Bellicum: Consultancy, Membership on an entity's Board of Directors or advisory committees; bluebird bio: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Parasole:Baxalta: Membership on an entity's Board of Directors or advisory committees; behring: Consultancy; jazz: Honoraria, Speakers Bureau.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gfydsl发布了新的文献求助20
1秒前
小豆包发布了新的文献求助10
1秒前
1秒前
虚心发布了新的文献求助10
2秒前
结实的鸵鸟完成签到 ,获得积分10
2秒前
fdwonder完成签到,获得积分0
2秒前
Tom完成签到,获得积分10
2秒前
落寞绝音完成签到,获得积分10
2秒前
冰糖完成签到 ,获得积分10
2秒前
4秒前
4秒前
4秒前
4秒前
5秒前
Moonlight完成签到 ,获得积分10
5秒前
悠悠球完成签到,获得积分10
5秒前
落寞绝音发布了新的文献求助10
5秒前
vetzlk完成签到 ,获得积分10
6秒前
6秒前
7秒前
luocan发布了新的文献求助10
7秒前
7秒前
六边形猪宝完成签到 ,获得积分10
8秒前
蔚欢完成签到 ,获得积分0
8秒前
9秒前
SD512T发布了新的文献求助10
9秒前
kkk完成签到 ,获得积分10
10秒前
Jerry完成签到 ,获得积分10
10秒前
慕青的应助被richardhipower采纳,获得10
10秒前
敏感代云完成签到,获得积分10
10秒前
田様的应助被tian采纳,获得30
11秒前
木子完成签到,获得积分10
11秒前
硫酸盐发布了新的文献求助10
11秒前
李洪杰发布了新的文献求助10
11秒前
listen发布了新的文献求助10
11秒前
王小白发布了新的文献求助30
12秒前
白华苍松发布了新的文献求助10
12秒前
12秒前
phobeeee完成签到 ,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699